ATE22658T1 - Praeparate fuer die behandlung der seitlichen amyotrophischen sklerose, der parkinsonkrankheit und der alzheimerkrankheit mit nervenstaerkenden faktoren. - Google Patents

Praeparate fuer die behandlung der seitlichen amyotrophischen sklerose, der parkinsonkrankheit und der alzheimerkrankheit mit nervenstaerkenden faktoren.

Info

Publication number
ATE22658T1
ATE22658T1 AT82306343T AT82306343T ATE22658T1 AT E22658 T1 ATE22658 T1 AT E22658T1 AT 82306343 T AT82306343 T AT 82306343T AT 82306343 T AT82306343 T AT 82306343T AT E22658 T1 ATE22658 T1 AT E22658T1
Authority
AT
Austria
Prior art keywords
disease
specific
hormones
alzheimer
neurotrophic
Prior art date
Application number
AT82306343T
Other languages
English (en)
Inventor
Stanley Hersh Appel
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Application granted granted Critical
Publication of ATE22658T1 publication Critical patent/ATE22658T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT82306343T 1981-12-22 1982-11-29 Praeparate fuer die behandlung der seitlichen amyotrophischen sklerose, der parkinsonkrankheit und der alzheimerkrankheit mit nervenstaerkenden faktoren. ATE22658T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8138627 1981-12-22
EP82306343A EP0082612B1 (de) 1981-12-22 1982-11-29 Präparate für die Behandlung der seitlichen amyotrophischen Sklerose, der Parkinsonkrankheit und der Alzheimerkrankheit mit nervenstärkenden Faktoren

Publications (1)

Publication Number Publication Date
ATE22658T1 true ATE22658T1 (de) 1986-10-15

Family

ID=10526778

Family Applications (1)

Application Number Title Priority Date Filing Date
AT82306343T ATE22658T1 (de) 1981-12-22 1982-11-29 Praeparate fuer die behandlung der seitlichen amyotrophischen sklerose, der parkinsonkrankheit und der alzheimerkrankheit mit nervenstaerkenden faktoren.

Country Status (10)

Country Link
EP (1) EP0082612B1 (de)
JP (1) JPS58154514A (de)
AT (1) ATE22658T1 (de)
CA (1) CA1223513A (de)
DE (1) DE3273612D1 (de)
DK (1) DK560682A (de)
ES (1) ES518386A0 (de)
FI (1) FI824276L (de)
IL (1) IL67313A0 (de)
ZA (1) ZA828932B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017375A (en) * 1982-11-24 1991-05-21 Baylor College Of Medicine Method to prepare a neurotrophic composition
EP0258111A3 (de) * 1986-08-07 1989-01-25 FIDIA S.p.A. Neuronotrophischer Faktor
US5218094A (en) * 1986-08-07 1993-06-08 Fidia, S.P.A. Neuronotrophic factor derived from mammalian brain tissue
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
FR2657784A1 (fr) * 1990-02-05 1991-08-09 Pasteur Institut Facteur endogene cerebral, procede d'obtention et applications therapeutiques et diagnostiques.
US5898066A (en) * 1994-08-26 1999-04-27 Children's Medical Center Corporation Trophic factors for central nervous system regeneration
US20060153797A1 (en) * 2004-06-11 2006-07-13 Bortolotto Susan K Tissue material and matrix

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE639638C (de) *
DE560325C (de) * 1929-06-08 1932-10-01 Schering Kahlbaum Ag Verfahren zur Herstellung eines die zentralen Taetigkeiten foerdernden und regulierenden Reizstoffes aus waessrigen Auszuegen von Wirbeltierhirn oder dessen Zubereitungen
DE1095464B (de) * 1956-05-22 1960-12-22 Univ Tulane Verfahren zur Herstellung eines Heilmittels zur Behandlung von Schizophrenie und anderen Geisteskrankheiten
US3989819A (en) * 1969-03-05 1976-11-02 American Cyanamid Company Process for separating proteins from central nervous system tissue and treating experimentally induced demyelinating diseases

Also Published As

Publication number Publication date
ES8406499A1 (es) 1984-08-01
JPS58154514A (ja) 1983-09-14
ZA828932B (en) 1984-03-28
FI824276A0 (fi) 1982-12-13
IL67313A0 (en) 1983-03-31
DK560682A (da) 1983-06-23
EP0082612B1 (de) 1986-10-08
EP0082612A1 (de) 1983-06-29
ES518386A0 (es) 1984-08-01
FI824276A7 (fi) 1983-06-23
FI824276L (fi) 1983-06-23
DE3273612D1 (en) 1986-11-13
CA1223513A (en) 1987-06-30

Similar Documents

Publication Publication Date Title
Loebel et al. Duration of psychosis and outcome in first-episode schizophrenia.
NL300140I1 (nl) Galanthamine, of verbindingen die eraan analoog zijn, voor behandeling van de ziekte van Alzheimer.
Pass et al. Elastosis perforans serpiginosa during penicillamine therapy for Wilson disease
DE68912419D1 (de) Verwendung von Uridin zur Behandlung nervöser Störungen.
KR920701432A (ko) 뇌유도성 향신경성 인자
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
BE904922A (fr) Procedes de traitement de troubles gastro-intestinaux infectieux.
DE69532482D1 (de) Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda-antagonisten enthält
DE69628912D1 (de) Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer
ATE176400T1 (de) Therapeutische verwendungen von melanin
ATE241354T1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
FR2395296A1 (fr) Utilisation d'esters d'acides carboxyliques et d'alkylolamines tertiaires pour le traitement de pigments en matieres de charge inorganiques dont on veut ameliorer la dispersabilite
ATE22658T1 (de) Praeparate fuer die behandlung der seitlichen amyotrophischen sklerose, der parkinsonkrankheit und der alzheimerkrankheit mit nervenstaerkenden faktoren.
FR2372205A1 (fr) Composition de latex dont une partie du polymere a ete remplacee par de l'amidon specialement traite
Friel Familial incidence of Gilles de la Tourette's disease, with observations on aetiology and treatment
EP0267676A3 (de) Verwendung von 1,3-Di-n-butyl-7-(2-oxypropyl)xanthin zur Behandlung von zerebrovaskulären oder mit zerebraler Senilität assoziierten Störungen, von peripherer Gefässkrankheit und proliferativen Hautkrankheiten
DE69431050D1 (de) PYRIDO[2,3-b](1,4)BENZODIAZEPINONE ALS M2-REZEPTORLIGAND ZUR BEHANDLUNG NEUROLOGISCHER STÖRUNGEN
Gaddy et al. Differential behavioral changes following intrastriatal application of 6-hydroxydopamine.
DE68928169D1 (de) Zusammensetzung zur Behandlung von degenerativen Krankheiten des Nervensystems
DE58901872D1 (de) Neue kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
FI901371A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten halogeeni-3,4-dihydro-bentsotiopyranyyliamiinien valmistamiseksi
Klug Hypnosis as a treatment modality in psychiatric practice.
Lynch Functional recovery after lesions of the nervous system. 3. Developmental processes in neural plasticity. The formation of new synaptic connections after brain damage and their possible role in recovery of function
Sheldon Spirituality, healing and medicine
Zapletalek et al. Maintenance treatment of schizophrenia with oxyprothepine decanoate: Double-blind comparison with standard.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties